1. Home
  2. UONEK vs RNTX Comparison

UONEK vs RNTX Comparison

Compare UONEK & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urban One Inc. Class D

UONEK

Urban One Inc. Class D

HOLD

Current Price

$0.85

Market Cap

36.9M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc. Common Stock

HOLD

Current Price

$1.36

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UONEK
RNTX
Founded
1980
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.9M
38.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UONEK
RNTX
Price
$0.85
$1.36
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
1.1M
236.7K
Earning Date
11-04-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$393,670,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$1.04
52 Week High
$1.40
$3.50

Technical Indicators

Market Signals
Indicator
UONEK
RNTX
Relative Strength Index (RSI) 61.14 46.39
Support Level $0.80 $1.15
Resistance Level $0.92 $1.58
Average True Range (ATR) 0.12 0.11
MACD 0.01 -0.01
Stochastic Oscillator 65.20 48.84

Price Performance

Historical Comparison
UONEK
RNTX

About UONEK Urban One Inc. Class D

Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: